Beyond CRISPR: TALEN, smart cells, and the regulatory edge in gene editing

“Success in gene editing is not only about having strong backbones or optimizing specificity, it is also about delivering these tools in a way that ensures performance and precision.”

In this discussion, Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to David Sourdive, Executive Vice President, CMC & Manufacturing, Cellectis, who shares insights into the company’s pioneering work in gene editing and allogeneic CAR-T cell therapies. With considerations surrounding the regulatory CMC space, they explore how smart cell innovation is shaping the future of gene editing.

Please enter your email to access content Read now